Objectives: Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants.
Introduction
Invasive aspergillosis (IA) develops in 5%-10% of patients treated for acute leukaemia and in up to 40% of recipients of allogeneic haematopoietic stem cell transplants (HSCTs). 1 -3 Although recent data suggest improved survival, 2 in general IA-associated mortality ranges between 50% and 80% in patients with leukaemia and up to 70% in HSCT recipients. biopsies from sterile sites. As a consequence the European Organization for Research and Treatment of Cancer Infectious Disease Group and the Mycoses Study Group (EORTC-MSG) proposed consensus definitions for different levels of diagnostic certainty. 8 These criteria, recently updated, 9 take into account patient risk of developing IA, suggestive clinical presentation, laboratory data and imaging tests. According to the old criteria, the diagnosis of probable IA requires microbiological data supporting the likelihood of disease, including a positive culture and microscopy from a non-sterile site. The new definitions have added a positive galactomannan (GM) and/or glucan test as able to support a diagnosis of probability. The two largest randomized clinical trials of IA to date included many patients based on suggestive radiological imaging, without any microbiological confirmation. 10, 11 Caspofungin has proved effective for salvage therapy of IA and it has been approved for this indication. Caspofungin is very well tolerated, even in patients with severe underlying conditions. 12 However, there were very little published data about the efficacy of caspofungin as first-line therapy. For this reason, we found it important to perform a clinical trial aimed at estimating the efficacy of caspofungin as first-line monotherapy of patients with proven or probable IA, as defined by strict EORTC-MSG criteria. Patients with haematological malignancies and autologous HSCT (Group 1) and patients with allogeneic HSCT (Group 2) were included in two different strata and evaluated separately, because response rates (RRs) and survival differ substantially in these populations. In the present article we report results among patients with haematological malignancies or undergoing autologous HSCT. Results from patients with allogeneic HSCT will be reported separately due to the very different nature of the patient populations and underlying diseases. Data about haematological patients were presented at the TIMM (Trends in Medical Mycology) Congress in Torino 2007 as an oral presentation by C. V.
Methods
This was a Phase II, open label, non-comparative, multicentre study to estimate the efficacy of caspofungin as first-line monotherapy for IA in patients with haematological malignancies or undergoing autologous HSCT. Twenty centres in Europe participated in the study, which was approved by the Protocol Review Committee of the EORTC (EORTC and EudraCT protocol numbers 65041 and 2004-002944-90, respectively) and by the Ethics Committees of each participating institution. Written informed consent was required and enrolment was centralized at the EORTC Data Centre using a secure web-based system. All case reports were computerized at the EORTC Data Centre in Brussels, Belgium and reviewed by a Data Review Committee (DRC) for completeness, accuracy, eligibility criteria and assessment of the outcome variables. The study was funded by an unrestricted educational grant by Merck & Co. One representative from Merck participated in DRC meetings, with no voting rights. Patients received a 70 mg loading dose of caspofungin on day 1, followed by 50 mg/day for at least 15 days (or until failure) and up to 84 days. Dose modifications were made for patients with body weight .80 kg (70 mg/day), moderate hepatic failure (70 mg loading dose followed by 35 mg/day) and concomitant administration of liver inducers able to influence caspofungin concentrations. Addition or modification to protocol therapy in the absence of efficacy assessment was considered treatment failure.
Evaluations included medical history, physical examination, Karnofsky score, haematology and chemistry profiles at baseline, weekly and up to 30 days after treatment. In addition, Aspergillus GM-ELISA test, blood cultures, sputum cultures, bronchoalveolar lavage (BAL), aspiration of pulmonary and extrapulmonary lesions, CSF examination, chest X-rays, sinus or lung CT scans were performed as clinically appropriate. GM tests were performed at least every 48 h, if possible, especially during the upgrading phase. For the purpose of this trial a GM test of 0.7 was considered positive, a value that was the most widely used when the study was conceived. Two positive, consecutive samples in blood or one positive sample in BAL were needed in order to contribute to a diagnosis of probable infection.
Study design and entry criteria
The study design is shown in Figure 1 . The study included patients with haematological malignancies in any stage, including patients with an underlying disease not in remission (relapsing or refractory) and with probable or proven IA, strictly according to the EORTC-MSG definitions, with the only exception being that the GM test was allowed as a confirmation test for probable aspergillosis. Patients with possible IA (i.e. those with a halo sign only, without microbiological confirmation or with host factors and clinical signs or symptoms compatible with IA but again without microbiological confirmation) were allowed to start treatment. However, investigators had 7 days to upgrade the case to proven or probable IA based on culture or serological tests performed prior to or within 48 h after registration, but with results pending. Patients not upgraded were discontinued from the study; these patients were assessed for safety but not for efficacy. Other entry criteria included age 18 years and not having received either an investigational agent within 14 days prior to registration or an empirical antifungal therapy (not including an echinocandin) for .72 h before inclusion. Oral prophylaxis had to be discontinued at study entry. No intravenous prophylaxis was allowed, unless with fluconazole. A history of allergy to echinocandins, severe renal failure, significant liver function test abnormalities, severe hepatic insufficiency, inadequately treated bacterial infection, documented HIV infection, status of pregnancy or lactation, conditions hampering compliance and a Karnofsky score of 20 were exclusion criteria.
Response assessment criteria
The study was evaluated using standard response assessment criteria. 9 Briefly, every case was assessed by clinical and radiological criteria as having achieved complete or partial response (success), stabilization or disease progression (failure). The reduction in the sum of the area and longest diameter of all measurable lesions attributable to IA from baseline to end of therapy (EOT) was calculated as follows: [sum of the area (or longest diameter) at baselinesum of the area (or longest diameter) at EOT]/sum of the area (or longest diameter) at baseline.
A negative reduction indicated an increase in the lesion area or longest diameter. At least a 50% reduction in the size of the lesion was required to qualify the case as partial response, while a reduction of ,50% qualified the patient as having stable disease. The modified intention to treat (MITT) group included all patients with confirmed probable/proven IA who received at least one dose of caspofungin treatment.
Study endpoints and statistical planning
The primary endpoint was the proportion of MITT patients with complete or partial response to treatment at EOT. The secondary endpoints were response to treatment and survival at day 84 after enrolment, and safety, as defined by the proportion of drug-related adverse events, serious drug-related adverse events and drug-related adverse events leading to treatment discontinuation. The study was planned according to a one-stage Fleming design. Based on RRs observed in a previous study, 9 52 eligible and evaluable patients were needed, in order to show that the true RR was .35% (with a power of 95% in the case of a true RR of 55%), using a one-sided significance level of 10%. To reject the null hypothesis of a true RR of 35% (and therefore to recommend the tested regimen for further studies), 23 complete or partial responses out of 52 eligible patients were required (observed RR 44%). A non-eligibility rate of 10% and a non-upgrading rate of 30% were forecast; thus, the final sample size estimation was planned to include at least 87 patients. Fisher's exact test was used to test the statistical significance of differences in discrete data and the Mann-Whitney U-test to compare continuous variables such as Karnofsky score. P,0.05 was considered statistically significant. As most of the deaths attributable to IA occur by day 84, the binary survival status at day 84 was considered as an endpoint. A logistic regression model was constructed to determine baseline characteristics independently related to survival at day 84. The model took into account the granulocyte count at EOT, as well, with the consequence that the resulting logistic regression model cannot be used to predict survival status at start of treatment. Gender, Karnofsky score, status of underlying disease, diagnosis of IA, site of infection, prior antifungal therapy, being neutropenic at enrolment and EOT, and having been neutropenic for .10 days during the 60 days prior to enrolment were variables included in the analysis. The logistic regression model was obtained using stepwise forward selection of variables.
Results
In total, 129 patients were enrolled between 26 April 2005 and 31 March 2007. Sixty-eight patients were ineligible due to lack of microbiological criteria (n¼ 64) or absence of major or minor clinical criteria (n ¼ 4). The remaining 61 cases were evaluable for the MITT analysis, resulting in a statistical power of 0.97. In this study, 88 patients were initially registered as having possible aspergillosis. Of these, 24 (27%) were upgraded to proven or probable IA.
Baseline characteristics and demographics
As shown in Table 1 , all patients had a haematological malignancy treated with chemotherapy or autologous HSCT and were affected by proven or probable IA. Neutropenia (,500 cells/mm 3 ) at enrolment and/or for .10 days within the 60 days before was present in more than two-thirds of the patients. At EOT, the rate Pathogens isolated were Aspergillus fumigatus (n¼15), Aspergillus flavus (n¼2) and Aspergillus niger (n¼1). Two patients had two different species isolated. The most common clinical signs and symptoms were sputum production (92%), fever (77%), cough (67%), dyspnoea (51%) and chest pain (38%).
Outcomes
The mean duration of treatment was 27 days (SD +24), with a median duration of 15 days (range 3 -84). RRs at EOT are shown in Table 2 . Among the nine patients with stable disease at EOT, six survived day 84. Of them, two did not receive any additional antifungal treatment after 3 weeks of caspofungin and four received maintenance therapy with an oral azole (two itraconazole and two voriconazole). Response to treatment by baseline patient characteristics is shown in Table 3 . The Karnofsky score at the start of treatment had a statistically significant impact on the outcome (Mann -Whitney U-test; P ¼ 0.04). Although not statistically significant, more treatment failures were observed among patients with acute versus chronic leukaemia, with neutropenia at the start of study treatment and, especially, among those with a history of severe and prolonged neutropenia in the 60 days prior to enrolment (P ¼ 0.07). Survival data at day 84 are reported for 60 patients, with 1 patient lost to follow-up. The survival rates at 6 and 12 weeks were 66% (40/61) and 53% (32/60), respectively. The most common 12 week cause of death was IA, alone (n ¼ 18) or in association with other causes, such as haemorrhage (two cases), the underlying malignancy (five cases), a non-fungal concomitant infection (one case) and other causes (two cases). Variables significantly associated with survival at day 84 in the multivariate analysis were having an underlying disease in remission (not relapsing or refractory) at baseline (remission versus not in remission: OR 37.52; 95% CI 2.64 to .999), Karnofsky score at start of treatment (for each increase in the score the odds of survival increased by 88%, i.e. OR 1.88; 95% CI 1.12-3.58) and presence of neutropenia at EOT ( presence versus absence: OR 0.04; 95% CI ,0.001 -0.38). RRs of 16% (3/19) and 41% (16/39) were observed among patients who were and were not neutropenic at EOT, respectively (P¼ 0.08). Neutropenia at EOT was not assessable in three patients. Among the nine patients who were not neutropenic at the start of therapy, one was lost to follow-up. Five of the other eight (63%) survived to day 84. Antifungal prophylaxis and/or empirical therapy had no influence on response to treatment and survival, nor did the dose per weight of caspofungin administered.
Radiological assessments
Radiological assessments were available in 49 of 61 (80%) patients. Of the 12 patients with no radiological assessments at EOT, 11 had a clinical assessment of disease progression and one voluntarily refused treatment and was not assessed. In four patients, the radiological assessment was based on chest X-ray data only. Therefore, exact calculations of the change in size of the lesion were performed in 45 patients. Partial response was associated with a 73% (53% -90%) median decrease in the sum of the areas of all measurable lesions attributable to IA. A median 36% reduction was noted for patients with stable disease. Conversely, patients with disease progression differed significantly, with a median increase in the lesion size of 103% (95% CI 69 -421). No differences were demonstrated in terms of defervescence, sputum production, cough, dyspnoea and chest pain between responding and stabilized patients.
Safety
Of the 129 patients included in the safety analysis, 15% (n ¼ 19) had drug-related adverse events. There were no serious drug-related adverse events or drug-related adverse events leading to caspofungin discontinuation. Grade III or IV adverse events categorized as 'likely related' by the local investigator were all laboratory abnormalities in g-glutamyl transferase (n ¼ 5), alkaline phosphatase (n ¼ 4), bilirubin (n ¼ 2), aspartate aminotransferase (n¼ 1) and kalaemia (n¼ 3). No grade V adverse events were noted as 'likely related' by the local investigator.
Discussion
In our study 33% (95% CI 21 -46) of patients in the MITT analysis had a favourable response (complete and partial) at the end of caspofungin therapy. The role of the severity of the underlying disease was quite evident in this study. First, patients with acute leukaemia, Karnofsky score ,50 and neutropenia at the start of study treatment appeared less likely to have a favourable response. Secondly, the status of the underlying disease at baseline, the Karnofsky score and being neutropenic at EOT were all significantly associated with survival at day 84. These results suggest that in patients with persistent neutropenia and an underlying disease not in remission (relapsing or refractory), treatment of proven/probable IA presents a unique challenge. Response to treatment and survival were actually lower among patients with 'uncontrolled cancer (active malignancy)' than in other patients in the Ambiload study, as well. 11 The status of the underlying disease was also found to be one of the factors significantly associated with survival in a recent French study. 13 In terms of diagnostic certainty, this is the first trial to apply the EORTC-MSG criteria strictly. 8 We enrolled only patients with microbiological data supporting a diagnosis of proven/probable aspergillosis and excluded cases of possible disease (i.e. patients with halo sign only). This is important because better outcomes have been observed in patients enrolled solely on the basis of radiological signs than in patients with proven or probable disease.
14 Indeed, patients enrolled based on the presence of the halo sign only had better RRs than other patients in both the Phase II and III voriconazole studies and in the Ambiload study, 10, 11, 15 suggesting that at least some of the patients with radiological signs only actually do not have IA. It is important to note that requiring some microbiological confirmation of IA does not mean treating patients at a more advanced stage of disease, since treatment was always started at first clinical signs and empirical therapy was allowed, although for no longer than 72 h. Multivariable analyses showed that previous antifungal therapy or prophylaxis had no impact on response to treatment and survival.
Debate exists as to whether or not patients with stable disease should be considered as success of therapy. In our study, the main difference between stable disease and partial response was in the extent of decrease in the size of the lesions, with no difference in clinical outcomes, including GM values. As suggested in a recent position paper, given the severity of both the underlying condition and the complicating infection, there may be cases in which both physicians and patients might consider stable disease as an acceptable outcome. 16 This study was a non-comparative Phase II study designed to explore the efficacy of caspofungin as first-line therapy of IA. When the present study was designed, the only available model for setting reference RRs and calculating the sample size was the voriconazole versus amphotericin B study. 10 However, this choice, although forced, might have been inappropriate, because of the existence of important methodological differences between this study and the one we were planning. Indeed, the voriconazole study evaluated response to treatment at day 84, regardless of any therapeutic modification, and not at EOT, as in our study; it included both patients with haematological malignancies and allogeneic transplants and allowed the inclusion of patients lacking any microbiological or serological documentation of IA.
In conclusion, caspofungin achieved an EOT RR of 33% in the MITT population and a day 84 survival rate of 53%. We found that an underlying disease not in remission (relapsing or refractory), a Karnofsky score of ,50 and persistent neutropenia were all negatively associated with survival. While the planned null hypothesis of a true RR of 35% could not be rejected, it is possible that this was related to the very highrisk patient population included and to the choice of enrolling only patients with a high degree of disease certainty ( proven/ probable IA). Comparisons between trials are often impossible, because of the differences in definitions and patient populations and should, therefore, be interpreted with great caution. In this study, RRs at EOT and survival appeared to be slightly lower than those obtained with voriconazole and liposomal amphotericin B in patients with a similar disease certainty (with much better safety), but comparable to those obtained with the same drugs in patients with a similar underlying disease status. We do not know what the RR was in the voriconazole and liposomal amphotericin B trials among patients who had at the same time a true proven/probable disease and an advanced haematological neoplasm.
